Bladder cancer combo trial pulled before starting
NCT ID NCT07217496
First seen Oct 31, 2025 · Last updated May 19, 2026 · Updated 31 times
Summary
This early-stage trial was designed to test a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) in people with advanced bladder cancer that had not been treated before. The goal was to see if the combination was safe and could help control the cancer. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.